Back to Trials
NCT07529366Recruiting

Pharmacist-Led Continuous Glucose Monitoring for Prediabetes

University of South Florida

Start Date

6/1/2026

Completion Date

7/31/2027

Summary

The goal of this observational study is to determine if a pharmacist-led program involving continuous glucose monitoring (CGM) improves glucose control and health behavior in people with prediabetes. The main questions it aims to answer are: 1. Determine impact of pharmacist-led CGM on glycemic control in people with prediabetes. Researchers will compare change in hemoglobin A1c at 12 weeks with pharmacist-led CGM versus a historical cohort of subjects with prediabetes receiving no CGM. The investigators will also assess change in CGM-derived glycemic metrics from baseline to end of the CGM wear period in the intervention group. 2. Evaluate impact of pharmacist-led CGM on health behavior change in people with prediabetes in the intervention group. Participants will be asked to complete the Summary of Diabetes Self-Care Activities Measure (SDSCA) and 36-Item Short Form Health Survey (SF-36) at baseline, at the end of week 4, and at the end of the study so that researchers can measure the effects in the intervention group on health behavior change.

Eligibility Criteria

Age Range: 18 years to 70 years

Inclusion Criteria: * adults 18-70 years of age * prediabetes (HbA1c 5.7-6.4%) * compatible smartphone with the Dexcom Stelo sensor system * have not have worn a CGM in the last 6 months prior to enrollment Exclusion Criteria: * any of the following forms of diabetes: type 1 diabetes, type 2 diabetes, monogenic diabetes, cystic fibrosis-related diabetes, post- transplant diabetes, latent autoimmune diabetes * problematic hypoglycemia in the prior 6 months \[defined as recurrent (more than one) level 2 hypoglycemic events (glucose \<54mg/dL ) that persist despite multiple attempts to adjust medication(s) and/or modify the diabetes/treatment plan or a history of one level 3 hypoglycemic event (glucose \<54mg/dL) characterized by altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia\] * pregnant, or planning to become pregnant during the study time frame * currently receiving or planned to receive dialysis during the study time frame - current use of systemic steroids for any condition * a known allergy to medical grade adhesives, * use of any CGM device in the past 6 months * history of a diagnosed eating disorder * current use of a second-generation antipsychotic at the time of consent (aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) * subjects lacking capacity to provide informed consent

Interventions

DEVICE

Dexcom Stelo CGM

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Prediabetes

Locations

USF Health Department of Family Medicine - Morsani Center for Advanced Health Care

Tampa, Florida 33612

United States

USF Health Department of Family Medicine - University Partnership Center

Tampa, Florida 33613

United States